Dd-cfDNA Trajectories Flag Kidney Transplant Risk
A 1,137-patient registry study links persistent donor-derived cell-free DNA elevations to higher rejection and graft loss.
Updated on Nov. 16, 2026 in Allergies

Researchers published a prospective multicenter study on donor-derived cell-free DNA trajectories in kidney transplant recipients in Transplantation. Persistent and late dd-cfDNA elevations in the first 4 months were associated with higher rates of graft rejection and graft loss over 3 years.
Why it matters
The findings suggest early dd-cfDNA monitoring could help identify transplant recipients at higher risk of rejection and graft failure. Clinicians may use trajectory patterns, not just single measurements, to guide follow-up.
The study followed 1,137 kidney transplant recipients for 3 years, with graft loss at 20.0% in the persistent-elevation group. Whether acting on these trajectories would improve outcomes is not addressed by the findings.
The players
Allegheny General Hospital
A Pittsburgh, Pennsylvania hospital whose affiliated investigators led the study.
The details
The Kidney Outcomes AlloSure Registry data classified recipients into four dd-cfDNA trajectory groups during the first 4 months after transplantation. Investigators tracked donor-specific antibodies, biopsy-proven rejection, graft dysfunction and graft loss, with results adjusted for calculated panel reactive antibody and retransplantation.
Timeline
First 4 months after transplantation: dd-cfDNA trajectories were measured.
3 years: follow-up period for graft outcomes.
November 2, 2026: results were published online in Transplantation.
Health Landscape
The study draws on the Kidney Outcomes AlloSure Registry, extending its surveillance data to analyze dd-cfDNA as a time-based trajectory rather than a single reading. This moves transplant monitoring toward longitudinal pattern recognition across the recipient population.
Transplant recipients with persistent dd-cfDNA elevations may face higher rates of rejection and graft dysfunction over three years. The findings may inform how often these patients are monitored after surgery.
The takeaway
Serial dd-cfDNA measurements may reveal risk patterns that single tests miss, offering clinicians an earlier signal in kidney transplant follow-up.
Further reading
Explore more on Allergies for related medical context.
Source note: This article includes information reported by Renal and Urology News.



